CLINICAL RESEARCH: ATHEROSCLEROSIS
Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women
The EPIC-Norfolk Prospective Population Study
Karim El Harchaoui, MD*,
Wim A. van der Steeg, MD*,
Erik S.G. Stroes, MD, PhD*,
Jan Albert Kuivenhoven, PhD*,
James D. Otvos, PhD||,1,
Nicholas J. Wareham, MBBS, PhD ,
Barbara A. Hutten, PhD ,
John J.P. Kastelein, MD, PhD*,*,
Kay-Tee Khaw, MBBChir and
S. Matthijs Boekholdt, MD, PhD*
* Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
Medical Research Council Epidemiology Unit, Cambridge, United Kingdom
Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
|| LipoScience Inc., Raleigh, North Carolina
Manuscript received August 4, 2006;
revised manuscript received September 22, 2006,
accepted September 28, 2006.
* Reprint requests and correspondence: Dr. John J. P. Kastelein, F4.159-2, Department of Vascular Medicine, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. (Email: j.j.kastelein{at}amc.uva.nl).
OBJECTIVES: We assessed relations of low-density lipoprotein (LDL) particle number (LDL-P) and LDL particle size as measured by nuclear magnetic resonance spectroscopy with LDL cholesterol (LDL-C) and the risk of future coronary artery disease (CAD).
BACKGROUND: Whereas LDL-C is an established risk factor for CAD, its discriminative power is limited. Measuring LDL-P and size may have stronger associations with CAD than LDL-C.
METHODS: A nested case-control study was performed in the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk study, which comprises 25,663 subjects. Cases (n = 1,003) were individuals who developed CAD during 6 year follow-up. Control subjects (n = 1,885) were matched for age, gender, and enrollment time. Odds ratios (ORs) for future CAD were calculated, and we also evaluated whether LDL-P could improve the Framingham risk score (FRS) to predict CAD.
RESULTS: In univariate analyses, LDL-P (OR 2.00, 95% confidence interval [CI] 1.58 to 2.59) and non-high-density lipoprotein cholesterol (non–HDL-C) (OR 2.14, 95% CI 1.69 to 2.69) were more closely associated with CAD than LDL-C (OR 1.73, 95% CI 1.37 to 2.18). The additional value of LDL-P was lost after adjustment for HDL-C and triglyceride levels. Whereas LDL size was inversely related to CAD (OR 0.60, 95% CI 0.47 to 0.76), this relation was abolished upon adjustment for LDL-P. In a model adjusted for the FRS, LDL-P retained its association with CAD (p for trend 0.02).
CONCLUSIONS: In this large study of individuals with moderately elevated LDL-C, LDL-P was related to CAD on top of FRS as well as after adjusting for LDL-C. The additional value of LDL-P was comparable to non–HDL-C, and it was abolished after adjusting for triglycerides and HDL-C.
|
Abbreviations and Acronyms
| | apoB = apolipoprotein B | | BMI = body mass index | | CAD = coronary artery disease | | CI = confidence interval | | FRS = Framingham risk score | | HDL-C = high-density lipoprotein cholesterol | | LDL = low-density lipoprotein | | LDL-C = low-density lipoprotein cholesterol | | LDL-P = low-density lipoprotein-particle number | | NMR = nuclear magnetic resonance | | OR = odds ratio |
|
This article has been cited by other articles:
|
|
|
|
 
S. Mora
Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use
Circulation,
May 5, 2009;
119(17):
2396 - 2404.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ip, A. H. Lichtenstein, M. Chung, J. Lau, and E. M. Balk
Systematic Review: Association of Low-Density Lipoprotein Subfractions With Cardiovascular Outcomes
Ann Intern Med,
April 7, 2009;
150(7):
474 - 484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Nuzum and T. Merz
Macrovascular Complications of Diabetes Mellitus
Journal of Pharmacy Practice,
April 1, 2009;
22(2):
135 - 148.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Y. Tsai, N. Li, A. R. Sharrett, S. Shea, D. R. Jacobs Jr, R. Tracy, D. Arnett, V. Arends, and W. Post
Associations of Genetic Variants in ATP-Binding Cassette A1 and Cholesteryl Ester Transfer Protein and Differences in Lipoprotein Subclasses in the Multi-Ethnic Study of Atherosclerosis
Clin. Chem.,
March 1, 2009;
55(3):
481 - 488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Contois, J. P. McConnell, A. A. Sethi, G. Csako, S. Devaraj, D. M. Hoefner, and G. R. Warnick
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
Clin. Chem.,
March 1, 2009;
55(3):
407 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mora, J. D. Otvos, N. Rifai, R. S. Rosenson, J. E. Buring, and P. M Ridker
Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women
Circulation,
February 24, 2009;
119(7):
931 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Sniderman
We Must Prevent Disease, Not Predict Events
J. Am. Coll. Cardiol.,
July 22, 2008;
52(4):
300 - 301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
J. Am. Coll. Cardiol.,
April 15, 2008;
51(15):
1512 - 1524.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Kaess, M. Fischer, A. Baessler, K. Stark, F. Huber, W. Kremer, H. R. Kalbitzer, H. Schunkert, G. Riegger, and C. Hengstenberg
The lipoprotein subfraction profile: heritability and identification of quantitative trait loci
J. Lipid Res.,
April 1, 2008;
49(4):
715 - 723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Diabetes Care,
April 1, 2008;
31(4):
811 - 822.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Mudd, B. A. Borlaug, P. V. Johnston, B. G. Kral, R. Rouf, R. S. Blumenthal, and P. O. Kwiterovich Jr
Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease
J. Am. Coll. Cardiol.,
October 30, 2007;
50(18):
1735 - 1741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E Ratner, S. Parikh, and C. Tou
Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
Diabetes and Vascular Disease Research,
September 1, 2007;
4(3):
214 - 221.
[Abstract]
[PDF]
|
|
|
|
